Search Within

Department of Medicine

Formats
  1. Journal Article (19593)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (610)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22321)
  2. Hematologic Malignancies, Division of (13278)
  3. Center for Hematologic Malignancies (11061)
  4. GSK Faculty (10646)
  5. Survivorship Research (9330)
  6. Division of Subspecialty Medicine (7535)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1071)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2111)

More Publishers

Results (39622)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HLA associations with immunotherapy related endocrine toxicity
    Meeting Abstract

    Quandt, Z.; Thorball, C.; Middha, P.; Johnson, D. B.; Bejan, C. A.; Yao, L.; Xu, Y.; Hodel, F.; Stravodimou, A.; Shearer-Kang, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal, or bone metastases in the phase II VISION trial
    Meeting Abstract

    Reinmuth, N.; Mazieres, J.; Popat, S.; Paz-Ares, L. G.; Hook, E. S.; Hatswell, A.; Vlassak, S.; Johne, A.; Vioix, H.; Paik, P. K.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Multicenter, randomized phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy (CAR-T)
    Meeting Abstract

    Bock, A. M.; Raj, S.; Giri, S.; Leslie, L. A.; Patel, D. A.; Iqbal, M.; Grover, N. S.; Hu, B.; Perales, M. A.; Nowakowski, G. S.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Molecular characterization of NUT carcinoma: A report from the NUT carcinoma registry
    Meeting Abstract

    Luo, J.; Kim, J. J.; Walton, S. A.; Nguyen, T.; Paik, P. K.; Chaft, J. E.; Hsu, R.; Piha-Paul, S. A.; Janne, P. A.; Sholl, L. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Safety outcomes in adult patients with AML who achieved their first complete remission with GO prior to HSCT
    Meeting Abstract

    Bejanyan, N.; Ho, V.; Perales, M. A.; Kebriaei, P.; Kaur, M.; Zhang, M. J.; D'Amico, P. G.; Purcell, S.; Dorman, S.; Vandendries, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors
    Meeting Abstract

    Sands, J.; Tolaney, S. M.; Ueno, N. T.; Spira, A. I.; Yamamoto, N.; Janjigian, Y. Y.; Naito, Y.; Damodaran, S.; Meric-Bernstam, F.; Modi, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Impact of late immune effector cell associated hematotoxicity (ICAHT) and prolonged neutropenia after CAR-T therapy on infection and survival outcomes
    Meeting Abstract

    Zenner, M.; Lessans, S.; Rejeski, K.; Perales, M. A.; Maziarz, R. T.; Chen, A. I.; Porter, D. L.; Schuster, S. J.; McGuirk, J.; Bishop, M. R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer
    Meeting Abstract

    Chen, R. C.; Mazza, G. L.; Fruth, B.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T. B.; Appleman, L. J.; Weckstein, D. J.; Patnaik, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma
    Meeting Abstract

    Kelley, R. K.; Cleary, J. M.; Sahai, V.; Baretti, M.; Bridgewater, J. A.; Hua, Z.; Gliser, C.; Bian, Y.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC)
    Meeting Abstract

    Lee, J. M.; Spicer, J.; Nair, S.; Khattak, A.; Brown, M.; Meehan, R. S.; Shariati, N. M.; Deng, X.; Samkari, A.; Chaft, J. E.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save